- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
A new report by Allied Market Research (AMR), Global biosimilars/follow-on-biologics market (types, applications and geography)--Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013-2020, suggests the global biosimilars market could reach $35 billion by 2020 from the estimated $1.3 billion in 2013.
Germany-based CRO Accovion has expanded its European presence. The company, already active in more than 20 countries, has established a subsidiary in Milan, Italy, naming Verónica de Lázaro country director.
According to a new market report published by Transparency Market Research (TMR), E-Clinical Solution Software Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020, the e-clinical solution software market, valued at $3 billion in 2014, is expected to grow at a CAGR of 13.8% from 2014 to 2020 to reach an estimated value of $6.52 billion in 2020.
India-based GVK Biosciences has unveiled a new brand, Clinogent, in the clinical development industry. Clinogent provides end-to-end clinical development services, from bioequivalence studies for generic pharma to late phase patient-based clinical studies. It offers solutions to complex data analysis and medical communication problems.
AstraZeneca revealed its proposed designs for its new global R&D center and corporate headquarters in Cambridge, U.K. The facility, which will be located on the Cambridge Biomedical Campus (CBC), includes the global center, an R&D enabling building and an energy center.
Evidera, a global provider of health economics, outcomes research, market access, data analytics and epidemiology solutions, has announced the addition of Xavier Badia, M.D., M.P.H., Ph.D. Badia will be senior research leader and senior leader of market development for the growing Evidera team in Europe.
Dipexium Pharmaceuticals has initiated patient enrollment in the first of two pivotal phase III clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI.
Investigative site logistics and core business models vary dramatically.
Status: Recruiting, Condition Summary: Alzheimer Disease
The list has been updated through June 2014.
Comunicado de la FDA sobre la seguridad de los medicamentos: Estudio de la FDA de pacientes de Medicare encontró menor riesgo de derrame cerebral y muerte con Pradaxa (dabigatrán) en comparación con warfarina
[05-13-2014] En su estudio en curso del anticoagulante Pradaxa (dabigatrán), la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus sigla en inglés) completó recientemente un nuevo estudio en pacientes de Medicare en el que compara Pradaxa con un anticoagulante antiguo, warfarina (Coumadin, Jantoven y genéricos), para determinar el riesgo de accidente isquémico o derrame causado por un coágulo, hemorragia cerebral, hemorragia gastrointestinal severa, infarto de miocardio y muerte.
The Kirby Institute at the University of New South Wales (UNSW) Australia has lost longtime colleague, professor Joep Lange, who was among the almost three hundred people on Malaysian Airlines flight MH17 shot down on the Russian-Ukraine border.
Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have received a $2.5 million grant from the Agency for Healthcare Research and Quality (AHRQ) to establish a training program to improve the practice of healthcare in real-world settings.
The Clinical Trial Optimization System from TrialNetworks, now part of DrugDev, has launched its latest app, TrialNetworks Charting. TrialNetworks Charting provides sponsors and CROs with visual intelligence into the study’s progress toward goals by region, country and site.
Myos, a biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into an R&D agreement with Cloud Pharmaceuticals.
FDA Drug Safety Communication: FDA warns that cancer drug docetaxel may cause symptoms of alcohol intoxication after treatment
[6-20-2014] The U.S. Food and Drug Administration (FDA) is warning that the intravenous chemotherapy drug docetaxel contains ethanol, also known as alcohol, which may cause patients to experience intoxication or feel drunk during and after treatment.
Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA recomienda no usar lidocaína para el tratamiento del dolor por dentición y requiere nuevo Recuadro de advertencia
[6-26-2014] La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por su sigla en inglés) advirtió que la solución de lidocaína viscosa al 2 por ciento para uso oral y de venta con receta médica, no se debe usar en el tratamiento del dolor por dentición de bebés o niños.
FDA Drug Safety Communication: FDA recommends not using lidocaine to treat teething pain and requires new Boxed Warning
[6-XX-2014] The U.S. Food and Drug Administration (FDA) warns that prescription oral viscous lidocaine 2 percent solution should not be used to treat infants and children with teething pain.
The boards of AbbVie and Shire have reached agreement on the terms of a recommended combination of Shire with AbbVie that values Shire at approximately $54.61 billion.
Status: Recruiting, Condition Summary: Advanced Cancers